Therapy News and Research

RSS

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

SRI International, an independent nonprofit research and development organization, announced today that it has assumed responsibility for further clinical development of the TAS-108 breast cancer program, in cooperation with Taiho Pharmaceuticals Co., Ltd., a leading Japanese pharmaceutical company. Further clinical development will focus on the lead compound's registration for the treatment of tamoxifen and aromatase inhibitor-resistant breast cancers.

20 Aug 2010

Palliative care recipients live longer and in less pain, study finds

The New York Times: "In a study that sheds new light on the effects of end-of-life care, doctors have found that patients with terminal lung cancer who began receiving palliative care immediately upon diagnosis not only were happier, more mobile and in less pain as the end neared — but they also lived nearly three months longer.

20 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Study finds black women with SLE develop cardiovascular disease at early age

A recent study by researchers at Penn State College of Medicine found significant racial disparities in the age of systemic lupus erythematosus (SLE) patients at the time of hospital admission for cardiovascular disease (CVD) events and CVD-related death. Black women were youngest to both be admitted with CVD and to have an in-hospital death due to CVD.

20 Aug 2010

Renin test can predict appropriate drugs for BP patients: Study

Commonly prescribed drugs used to lower blood pressure can actually have the opposite effect-raising blood pressure in a statistically significant percentage of patients. A new study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that doctors could avoid this problem-and select drugs most suitable for their patients-by measuring blood levels of the enzyme renin through a blood test that is becoming more widely available. The study appears in the online edition of the American Journal of Hypertension.

20 Aug 2010

MUH performs first intracranial radiosurgery with Leksell Gamma Knife Perfexion system

Macquarie University Hospital (MUH) performed Australia's first Gamma Knife surgery with its new Leksell Gamma Knife Perfexion system, making it the country's first and only center capable of providing dedicated intracranial radiosurgery.

20 Aug 2010

Research marks new direction to treat Pneumocystis, inflammatory diseases

A drug to treat inflammation plays a surprising role reducing the level of infection caused by an opportunistic bug that is deadly for AIDS and cancer patients and others with weakened immune systems.

20 Aug 2010

Muscular Dystrophy Association awards $14.1M in new grants

The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants.

20 Aug 2010

FDA grants priority review designation of BENLYSTA for systemic lupus erythematosus treatment

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration has granted a priority review designation to BENLYSTA (belimumab) as a potential treatment for systemic lupus erythematosus.

20 Aug 2010

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today provided an update on the clinical development program for its proprietary product for non-muscle-invasive bladder cancer - Urocidin.

20 Aug 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Metagenics announces acquisition of Catalina Lifesciences

Metagenics, Inc., a San Clemente, California-based life sciences company, today announced its acquisition of Catalina Lifesciences, Inc., the Irvine, California-based maker of Bariatric Advantage.

20 Aug 2010

PharmaVentures announces global expansion of PharmaDeals Agreements

PharmaVentures, the company behind the PharmaDeals(R) range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.

19 Aug 2010

Innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells

Current HIV treatments do not eradicate HIV from host cells but rather inhibit virus replication and delay the onset of AIDS. However, a new research published in BioMed Central's open access journal, AIDS Research & Therapy describes an innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells. This approach if successful could lead into an anti-HIV therapy that will eradicate the virus.

19 Aug 2010

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

The prostate cancer community joins together in congratulating Us TOO International Prostate Cancer Education & Support Network in their 20th anniversary of continued prostate cancer support, education and advocacy.

19 Aug 2010

Celera Corporation releases review article on KIF6 gene variant for CHD

Celera Corporation today announced the publication of a review article on the KIF6 gene variant as a predictor of risk of coronary heart disease (CHD) and reduction of CHD events from statin therapy.

19 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

EHSI signs option with Regenevita for 'Neo Natal Progenitor Cell Expansion Technology'

Emerging Healthcare Solutions, Inc. announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion.

19 Aug 2010

Maternal stress contribute to an elevated risk for depression in offspring: Research

For more than a century, clinical investigators have focused on early life as a source of adult psychopathology. Although the hypothesized mechanisms have evolved, a central notion remains: early life is a period of unique sensitivity during which experience confers enduring effects.

19 Aug 2010

MD Anderson Cancer Center receives $20 million to advance research on targeted therapies

Dallas businessman and philanthropist H. Ross Perot has donated $20 million to The University of Texas MD Anderson Cancer Center for research to advance and design novel targeted therapies.

19 Aug 2010

Therapy News and Research

SRI and Taiho collaborate to advance clinical development of TAS-108 breast cancer program

Palliative care recipients live longer and in less pain, study finds

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Study finds black women with SLE develop cardiovascular disease at early age

Renin test can predict appropriate drugs for BP patients: Study

MUH performs first intracranial radiosurgery with Leksell Gamma Knife Perfexion system

Research marks new direction to treat Pneumocystis, inflammatory diseases

Muscular Dystrophy Association awards $14.1M in new grants

FDA grants priority review designation of BENLYSTA for systemic lupus erythematosus treatment

Bioniche provides update on Urocidin clinical development program for non-muscle-invasive bladder cancer

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Metagenics announces acquisition of Catalina Lifesciences

PharmaVentures announces global expansion of PharmaDeals Agreements

Innovative approach to eliminate HIV in host by targeted killing of only HIV infected cells

Us TOO International Prostate Cancer Education & Support Network recognized for 20 years of service

Celera Corporation releases review article on KIF6 gene variant for CHD

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

EHSI signs option with Regenevita for 'Neo Natal Progenitor Cell Expansion Technology'

Maternal stress contribute to an elevated risk for depression in offspring: Research

MD Anderson Cancer Center receives $20 million to advance research on targeted therapies

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News